Oncolytic adenoviral therapy for glioblastoma multiforme.

Adam M. Sonabend*, Ilya V. Ulasov, Y. Han, Maciej S. Lesniak

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Adenoviruses historically have been one of the main vectors used in human gene therapy. To date, the majority of brain tumor trials of these vectors have used replication-defective viruses. The relative lack of success obtained with replication-defective vectors has prompted a search for new and improved therapies. In this context, oncolytic (conditionally replicative) adenoviruses, which selectively bind and replicate only in tumor cells, have gained increasing importance. These adenoviruses, once they are rendered conditionally replicative by transductional and transcriptional modifications, offer significant promise for patients with malignant glioma. In this review, the authors discuss the genetic approaches to adenoviral modification and their applications in the field of neurooncology.

Original languageEnglish (US)
Pages (from-to)E19
JournalNeurosurgical focus
Issue number4
StatePublished - 2006

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Oncolytic adenoviral therapy for glioblastoma multiforme.'. Together they form a unique fingerprint.

Cite this